Crown Reserve Acquisition Corp. I Announces the Pricing of $150,000,000 Initial Public Offering

Rhea-AI Summary

Crown Reserve Acquisition Corp. I (Nasdaq: CRACU) priced a $150,000,000 initial public offering of 15,000,000 units at $10.00 per unit. Units begin trading on Nov 7, 2025 and the offering is expected to close on Nov 10, 2025, subject to customary conditions. Each unit contains one Class A share, one-half of a redeemable warrant and one Share Right convertible into one-fifth of a Class A share; whole warrants exercise at $11.50. An amount equal to $10.00 per unit will be deposited into a trust account. The company granted underwriters a 45-day option to purchase up to 2,250,000 additional units (15%). Management includes CEO/Chair Prashant Patel and CFO/director Eric Sherb.

Positive

• $150M IPO proceeds from 15,000,000 units
• Trust account holds $10.00 per unit at closing
• Nasdaq listing begins Nov 7, 2025 under CRACU
• Underwriters' 45-day 15% over-allotment option

Negative

• Units include 0.5 warrant per unit, creating potential dilution
• Company is a blank-check vehicle with no announced target
• Closing is not guaranteed and is subject to customary conditions

Insights

SPAC capital markets analyst

Priced SPAC IPO for Crown Reserve Acquisition Corp. I: 15,000,000 units at $10.00 totaling $150,000,000; neutral near-term investor impact.

The company sold 15,000,000 units at $10.00 per unit, depositing an equal amount per unit into a trust and granting underwriters a 45-day option for up to 2,250,000 additional units for over-allotment. Each unit contains one Class A share, one-half warrant and one Share Right that converts to one-fifth of a share on a business combination; whole warrants exercise at $11.50. The securities are expected to list on Nasdaq under the tickers CRACU (units), CRAC (shares), CRACW (warrants) and CRACR (rights).

Primary risks and dependencies are factual and discrete: successful closing (expected November 10, 2025), separation of unit components for trading on November 7, 2025, and completion of an initial business combination within the SPAC framework. The sponsor states focus areas of pharma, medical technology, medical equipment and healthcare IT; any effect on stakeholders depends entirely on the target chosen and deal terms.

Concrete items to watch: closing of the offering on or about November 10, 2025, any exercise of the 45-day over-allotment option, and the timeline or announcement for an initial business combination. Management and board members named include Prashant Patel, Eric Sherb, Michael Peterson, Donald G. Fell, Avinash Wadhwani, and Mayur Doshi.

Grand Cayman, Cayman Islands, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crown Reserve Acquisition Corp. I (the “Company”) announced today the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and begin trading tomorrow, November 7, 2025, under the ticker symbol “CRACU.” Each unit consists of one Class A ordinary share, one-half of one redeemable warrant, and one right (the “Share Right”) to receive one-fifth (1/5) of one Class A ordinary share upon the consummation of an initial business combination. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. No fractional shares will be issued in connection with the exchange of Share Rights. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities comprising the units begin separate trading, we expect that the Class A ordinary shares, warrants, and Share Rights will be listed on the Nasdaq under the symbols “CRAC”, “CRACW”, and “CRACR”, respectively. The offering is expected to close on November 10, 2025, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments, if any.

The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution but will focus on industries where the Company has core competencies and experiences, such as pharma, medical technology and medical equipment, and healthcare IT industries.

The Company’s management team is led by Prashant Patel, its Chief Executive Officer and Chairman, and Eric Sherb, its Chief Financial Officer and Director. In addition, the Board includes Michael Peterson, Donald G. Fell, Avinash Wadhwani, and Mayur Doshi.

Polaris Advisory Partners, a division of Kingswood Capital Partners LLC, is acting as the sole book-running manager for the offering. In addition, Thunder Rock Capital, LLC (https://www.thunderrockcapital.com), a division of Finalis Securities LLC, acted as an advisor to the Company’s management team.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained, by contacting Kingswood Capital Partners, LLC, 126 East 56th Street, Suite 22S, New York, NY 10022, or by calling 212-487-1080 or emailing Syndicate@kingswoodUS.com.

A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on September 26, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds will be used as indicated.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

Crown Reserve Acquisition Corp. I
Eric Sherb
Chief Financial Officer

Conyers Trust Company (Cayman) Limited
PO Box 2681
Grand Cayman KY1-1111,
Cayman Islands
Tel: (813) 501-3533

FAQ

What did Crown Reserve Acquisition Corp. I (CRACU) price its IPO at and how many units were offered?

The company priced 15,000,000 units at $10.00 per unit for a $150,000,000 IPO.

When will CRACU begin trading on Nasdaq and under which ticker?

Units begin trading on Nov 7, 2025 on Nasdaq under the ticker CRACU.

What does each CRACU unit contain and what is the warrant exercise price?

Each unit contains one Class A share, one-half of a redeemable warrant, and one Share Right; whole warrants are exercisable at $11.50 per share.

When is the offering expected to close and are there any over-allotment options for CRACU?

The offering is expected to close on Nov 10, 2025, and underwriters have a 45-day option to buy up to 2,250,000 additional units.

How much cash will be held in trust for CRACU and what does that mean for investors?

An amount equal to $10.00 per unit will be deposited into a trust account to secure IPO proceeds until an initial business combination.

Who are the named executives for Crown Reserve Acquisition Corp. I (CRACU)?

Management is led by Prashant Patel (CEO and Chairman) and Eric Sherb (CFO and Director).